Key result
Atorvastatin 10 mg/day for 3 years did not significantly attenuate oxidative stress biomarkers vs placebo in CKD patients (F2-isoprostanes MD 5.3 pg/mL, 95% CI -29.2 to 39.8; P>0.05).
RCT (n=120)
Double-blind
Randomized
AIM: Statins have pleiotropic effects that include attenuation of oxidative stress that may be relevant for chronic kidney disease (CKD) patients. We investigated the effect of long-term atorvastatin therapy on oxidative stress biomarkers in CKD patients. METHODS: This was a pre-specified secondary analysis of data from a randomized, double-blind, placebo-controlled trial (Lipid lowering and Onset of Renal Disease, LORD) in CKD patients. Participants received 10 mg/day atorvastatin (n = 47) or placebo (n = 39) for 3 years. Plasma measures (total F2-isoprostanes, malondialdehyde. protein carbonyls, uric acid, glutathione peroxidase (GPx) activity and total antioxidant capacity (TAC) ) were performed at baseline and at 3 years. Age and sex matched participants (n = 34) with normal kidney function were controls. RESULTS: CKD patients had significantly (P < 0.05) increased F2-isoprostanes and uric acid and decreased GPx activity compared with controls. When comparing the treatment (atorvastatin (A) vs placebo (P) ) change from baseline to 3 years, there were no significant differences (P > 0.05) in the group difference of the change values: (mean (95% CI), F2-isoprostanes = 5.3 (-29.2 to 39.8) pg/mL, protein carbonyls = 0.03 (-0.13 to 0.19) nmol/mg, GPx activity = -0.10 (-4.73 to 4.52) (U/L), uric acid = 8.8 (-33.9 to 51.6) μmol/L or TAC = -0.03 (-0.10 to 0.04) mmol/L. A significant difference (P = 0.04) in the change in malondialdehyde between groups, 1.52(0.09 to 2.96) μmol/L, was due to a large decrease in the placebo group. CONCLUSION: CKD patients had elevated oxidative stress that was not attenuated by atorvastatin 10 mg/day for 3 years.
No takes yet. Share an insight, caveat, or question.
Fassett et al. (2015) conducted an RCT in Chronic kidney disease (n=120). Atorvastatin vs. Placebo was evaluated on Change in plasma oxidative stress biomarkers (total F2-isoprostanes, malondialdehyde, protein carbonyls, uric acid, glutathione peroxidase activity, total antioxidant capacity) at 3 years (MD 5.3 pg/mL (F2-isoprostanes), 95% CI -29.2 to 39.8, p=>0.05). Atorvastatin 10 mg/day for 3 years did not significantly attenuate oxidative stress biomarkers vs placebo in CKD patients (F2-isoprostanes MD 5.3 pg/mL, 95% CI -29.2 to 39.8; P>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: